CTIS2024-510981-18-00进行中（未招募）1 期
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiority, controlled trial (FREEDOM) - APHP231089
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 334
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Adult patients (=18 years old) •Documented MM in relapse according to standard criteria. •All patients must have received between 1 to 3 prior therapies for MM (a prior therapy is defined as 2 or more cycles of therapy given as a MM treatment plan •Eligible for one of the following antibody-based approved combinations (see 2.6 for details on EMEA authorization): (1) ICARIA schema: isatuximab, pomalidomide and dexamethasone. (2) IKEMA schema: isatuximab, carfilzomib and dexamethasone •Subject must have achieved a response (PR or better) to the prior regimen. •ECOG Performance Status score of 0, 1, or 2. •For subjects experiencing toxicities resulting from previous therapy (including peripheral neuropathy), the toxicities must have been resolved or stabilized. •Signed informed consent
排除标准
- •Contraindications to investigational medicinal products or auxiliary medicinal product •Evidence of refractoriness or intolerance to anti-CD38 monoclonal antibodies. •Previous treatment according to the ICARIA schema with pomalidomide orIKEMA schema with carfilzomib •Allogenic hematopoietic cell transplant (HCT, regardless of timing). •Planned to undergo an HCT prior to progression of disease ie, these patients should not be enrolled in order to reduce disease burden prior to transplant. •History of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator is considered cured with minimal risk of recurrence within 3 years). •Known MM meningeal Involvement. •Plasma cell leukemia (>2.0 × 109/L circulating plasma cells by standard differential) or Waldenström’s macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis. •Any concurrent medical condition or disease (e.g., active systemic infection) that is likely to interfere with study procedures or results, or that, in the opinion, of the Investigator would constitute a hazard by participating in this study. •Uncontrolled chronic obstructive pulmonary disease (COPD) •Clinically significant cardiac disease. •Seropositive for hepatitis B with positive PCR •Seropositive for human immunodeficiency virus (HIV) or hepatitis C. •Creatinine clearance =30 mL/min •Pregnancy or absence of effective contraceptive method for women of childbearing potential •Lactation •Participation to another interventional clinical trial •Inability to give written informed consent
研究者
相似试验
招募中
2 期
A randomised controlled trial of Dexamethasone for Emergency and Life-Threatening Admissions due to COVID-19 in Virtual Care: the DELTA studyCOVID-19 Delta VariantInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesEmergency medicine - Other emergency careACTRN12621001200875Royal Prince Alfred Hospital650
进行中（未招募）
1 期
Effect of dexamethasone (DXM) therapy in patients with a brain bleed: A comparision of a non-operative treatment versus surgery on patient recovery.EUCTR2015-001563-39-NLMedical Centre Haaglanden (MCH)170
招募中
3 期
Dexamethasone (DXM) therapy in symptomatic patients with chronic subdural hematoma (DECSA- Trial). Effect of initial corticosteroid therapy versus primary surgery on clinical outcome.Chronic subdural hematomableeding within the skull.1000796310009720NL-OMON55350Haaglanden Medisch Centrum420
已完成
不适用
Evaluation of the effects of using Dexamethasone impregnated gel foam and local injection of Dexamethasone in reduction of post impacted third molar surgery side effects in patients referring to Bushehr University of Medical Sciences Dental clinicCondition 1: Post opreative pain. Condition 2: Trismus.Other specified disorders of teeth and supporting structuresCramp and spasmK08.8R25.2IRCT20201101049209N1Boushehr University of Medical Sciences114
进行中（未招募）
1 期
DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumoniaHospitalized patients with Covid-19 pneumonia who do not require oxygen therapy on admission associated with at least two of the three following factors related with severe Covid-19: lactate dehydrogenase > 245 U/L, C-reactive protein > 100 mg/L and lymphocyte count < 800 cells/µL.EUCTR2021-001028-16-ESFundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive126